Cargando…
Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma
Neoadjuvant therapy with ipilimumab in combination with high dose IFNα was evaluated in patients with locally/regionally advanced melanoma in a previously reported clinical trial [NCT01608594]. In this study, peripheral immune cell profiling was performed in order to investigate the underlying mecha...
Autores principales: | Khunger, Arjun, Sarikonda, Ghanashyam, Tsau, Jennifer, Pahuja, Anil, Alfonso, Zeni, Gao, Jane, Laing, Christian, Vaupel, Christine, Dakappagari, Naveen, Tarhini, Ahmad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810775/ https://www.ncbi.nlm.nih.gov/pubmed/33450703 http://dx.doi.org/10.1016/j.tranon.2021.101014 |
Ejemplares similares
-
CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma
por: Khunger, Arjun, et al.
Publicado: (2021) -
Immune inhibitory function of bovine CTLA-4 and the effects of its blockade in IFN-γ production
por: Watari, Kei, et al.
Publicado: (2019) -
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
por: Tarhini, Ahmad
Publicado: (2013) -
CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010) -
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)